Date Mailed: April 4, 2003

Sheet 1 of 2 Attached to #25

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.5USWO	Application Number: 09/117,071
	Applicant: Kingsman et al.	
	Filing Date: 09/25/1998	Group Art Unit: 1636

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SE	US 6,503,501 B1	01/07/03	Anderson et al.	424	93.2	5/13/99

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
SE		Brigham et al., 2000, *Hum. Gene Ther.*, 11:1023-32 Transfection of nasal mucosa with a normal alpha 1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy
SE		Caplen et al., 1995, *Nat. Med.*, 1:39-46 Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
SE		Gleich et al., 1998, *Arch Otolaryngol Head Neck Surg.*, 124:1097-104 Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial
SE		Habib et al., 1996, *Cancer Detect. Prev.*, 20:103-7 Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas
SE		Hui et al., 1997, *Gene Therapy*, 4:783-790 Phase I study of immunotherapy of cutaneous metastases of human cacinoma using allogeneic and xenogeneic MHC DNA-liposome complexes
SE		Laitinen et al., 2000, *Hum. Gene Ther.*, 11:263-70 Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
SE		Merrouche et al., 1995, *J. Clin. Oncol.*, 13:410-8 Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin
SE		Nabel et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:11307-11311 Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
SE		Onodera et al., *Blood*, 1998, 91:30-36 Successful Peripheral T-Lymphocyte-Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase Deficiency
		Pages from www.wiley.co.uk/genetherapy/clinical

EXAMINER [signature] DATE CONSIDERED 11/3/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 9192.5USWO	Application Number: 09/117,071
	Applicant: Kingsman et al.	
	Filing Date: 09/25/1998	Group Art Unit: 1636

SK		Porteous et al., 1997, *Gene Ther.*, 4:210-218 Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
SK		Raper et al., 1996, *Annals of Surgery*, 223:116-126 Safety and Feasibility of Liver-Directed *Ex Vivo* Gene Therapy for homozygous Familial Hypercholesterolemia
SK		Sylvén et al., 2001, *Coronary Artery Disease*, 12:239-243 Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A_{165} plasmid in patients with inoperable angina pectoris

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.